Kathleen Sebelius - 10 Sep 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Director
Signature
/s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
10 Sep 2024
Net transactions value
-$77.87
Form type
4
Filing time
11 Sep 2024, 17:53:12 UTC
Previous filing
17 Jun 2024
Next filing
08 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Options Exercise $19,621 +4,521 +11% $4.34 43,910 10 Sep 2024 Direct
transaction HUMA Common Stock Sale $19,660 -3,634 -8.3% $5.41 40,276 10 Sep 2024 Direct F1
transaction HUMA Common Stock Options Exercise $8,305 +2,479 +6.2% $3.35 42,755 10 Sep 2024 Direct
transaction HUMA Common Stock Sale $8,344 -1,548 -3.6% $5.39 41,207 10 Sep 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Options Exercise $0 -4,521 -53% $0.000000 3,979 10 Sep 2024 Common Stock 4,521 $4.34 Direct
transaction HUMA Stock Options (right to buy) Options Exercise $0 -2,479 -29% $0.000000 6,021 10 Sep 2024 Common Stock 2,479 $3.35 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.